FDA puts Seattle Genetics drug trials on hold after 4 deaths

Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies. Six patients with acute myeloid leukemia , a type of blood cancer, have been identified with liver toxicity and four have died, the company said on Tuesday.